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ABSTRACT 
Background 
Endoscopic balloon dilatation is a recognised treatment for symptomatic Crohn’s strictures. Several case 
studies report its short term and long term efficacy.  A systematic analysis of the current literature is needed 
to define its overall efficacy and inform the design of future studies.  
Aim 
The primary objective was to examine symptomatic response, technical response and adverse events of 
endoscopic balloon dilatation. Stricture characteristics that may impact on outcome were also explored. 
Methods 
A systematic search strategy of COCHRANE, MEDLINE, EMBASE and OVID was performed.  All 
original studies reporting outcomes of endoscopic balloon dilatation for Crohn’s strictures in the adult 
population were included.  Pooled event rates across studies were expressed with summative statistics. 
Heterogeneity across studies was assessed numerically.   
Results 
25 studies were included capturing 1089 patients and 2664 dilatations.  The pooled event rates for 
symptomatic and technical response was 74.8% (95% CI: 69.9-79.3%; I2: 0%) and 90.6% (95% CI: 87.8-
92.8%; I2:11.7%), respectively. The pooled event rates for complications and perforations was 6.4% (95% 
CI: 5.0-8.2; I2:4.0%) and 3% (95% CI: 2.2-4.0%; I2:0%), respectively. Inflammatory activity and 
anastomotic strictures may be associated with lower symptomatic response and inflammatory activity with 
higher perforation rate.  
Conclusion  
The efficacy and complication rates of endoscopic balloon dilatation treatment for symptomatic Crohn’s 
strictures was higher than previously reported. Efficacy may be affected by active inflammation, previous 
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surgery and choice of outcome measure. Future studies should examine differential effects on stricture types 
using a clinically relevant outcome measure. 
Prospero Registration Number: CRD42015015758 
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INTRODUCTION 
Rationale 
Strictures in Crohn’s disease usually develop during the course of the disease 
[1 2]
 but in 5-27% of cases they 
are the presenting feature.
[2-5]
  Strictures may also arise following surgery.
[6]
  Both types may either be 
inflammatory or fibrotic or include both elements.  The majority (98.8%) are found in the colon, ileo-colonic 
region, and ileum after 10 years of disease. 
[6]
 
 
The understanding of the pathogenesis of fibrosis in Crohn’s disease is evolving. Chronic inflammation 
leads to thickening of the mucosa and narrowing of the gut lumen. 
[6-8]
  Thereafter, disruption in the normal 
extracellular matrix and irregular activity of fibroblasts contribute to an imbalance of collagen deposition. 
Anastomotic strictures on the other hand, develop through a combination of local and technical factors, such 
as bacterial stasis from postoperative narrowing of the lumen, high intraluminal pressures, or vascular 
compromise resulting in tissue ischemia, leaking, or infection which drive healing by tissue fibrosis. 
[9 10]
 
 
Environmental, genetic and serological factors are also implicated in the evolution of strictures. Smoking 
was associated with an increased rate of progression from inflammatory to stricturing disease in one 
study.
[11]
  In separate studies, mutations in the NOD2 gene were associated with small bowel fibro-stenosing 
Crohn’s Disease,
[12]
 whereas the NOD2/CARD15 genotype was an independent risk factor for early surgical 
intervention due to strictures.
[13]
  Antimicrobial antibodies are linked to complications in Crohn’s disease but 
are not restricted to stricturing disease.
[14]
  Further studies using animal models of intestinal fibrosis may 
offer further insights into the pathogenesis such as factors promoting of stricture progression, markers of 
early diagnosis and modulation of fibrosis pathway to arrest or reverse the process.
[8 15]
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Small bowel strictures have a greater impact on individuals than colonic strictures because of the narrower 
lumen and loss of absorptive surface.  Prompt therapy and preservation of small bowel are key factors in the 
management of small bowel CD strictures.  The ECCO consensus on management of Crohn's disease 
recommends resection, strictureplasty or balloon dilatation as alternatives after initial medical treatment for 
localised small bowel or ileo-colic disease.
[16]
  In clinical practice, the therapeutic choice is determined by 
stricture characteristics: accessible, short and anastomotic strictures are best considered for endoscopic 
balloon dilatation whereas endoscopically inaccessible, multiple and >5cm in length are suited to surgical 
approaches. Strictureplasty and bowel resection, carry short term risks of anastomotic leak, wound 
complications and the possibility of stoma formation and long term risks from recurrent disease, reoperation 
and short bowel.
[17 18]
  Balloon dilatation offers a more attractive option because of its ease of administration 
and low costs. There are risks associated with the dilatation procedure.  In short term risks, inability to 
completely dilate, perforation and bleeding, whereas long term risks are related to disease recurrence which 
may warrant further dilatation or surgery.
[19]
 
 
Several studies report outcomes of endoscopic balloon dilatation in Crohn’s disease strictures.
[20-44]
  These 
outcomes were collated in a systematic literature review published in 2007. The lack of pooled analysis of 
events rates and non-conformity with PRISMA guidelines
 
are discernible weaknesses of the review.
[19]
  
Moreover, since then a further 12 studies have been published.  
 
Objectives 
This systematic review was performed to describe the outcomes of endoscopic balloon dilatation for Crohn’s 
disease strictures to include additional studies.  The primary aim was to examine the pooled incidence of 
clinical response, technical response and adverse events following endoscopic balloon dilatation for Crohn’s 
strictures in adults.  The secondary aim was to explore the impact of stricture characteristics on outcomes.  
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METHODOLOGY 
Protocol and registration 
The protocol for this study was registered on PROSPERO (CRD42015015758).   
 
Eligibility Criteria 
All original studies, from 1991 to 2014, reporting outcomes of endoscopic balloon dilatation for Crohn’s 
disease intestinal strictures in the adult population (age ≥ 18) were included in the review.  Randomised 
controlled trials, observational reports and case series with sample size more than 5 were all included.  Case 
reports and studies reporting on multiple diagnoses were excluded from the review. Patients undergoing 
double balloon dilatation for deep seated intestinal strictures and children (age < 18) were more likely to 
require a general anaesthesia for the required intervention.  Studies reporting exclusively on these were also 
excluded.  
 
Information sources 
A three step search strategy was employed.  Initially a limited search was performed using PUBMED to 
identify keywords and index terms contained in the title or abstract.  The second step involved an extensive 
search using all identified keywords and extensive terms.  Studies were identified by searching the following 
databases: COCHRAINE, MEDLINE, EMBASE & OVID.   
 
Search 
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The final search terms were ("Crohn’s Disease" OR Crohn’s OR stricture OR “Montreal B2”) AND 
(endoscopy OR endoscopic OR ileocolonoscopy OR ileoscopic OR colonoscopy OR colonoscopic) AND 
(“balloon therapy” OR “balloon dilatation” OR balloon dilation” OR dilatation OR “balloon 
strictureplasty”).  The final step was a hand search of reference lists and bibliographies from previously 
retrieved studies to identify further relevant trials. 
 
Data collection process 
The first reviewer (PM) screened the titles and abstracts that were identified in the search strategy.  The 
papers were then evaluated by two reviewers (PM and NA) according to the eligibility criteria outlined 
above.  Discrepancies were resolved by consensus between the two reviewers.  Data from selected studies 
were extracted by the first reviewer and this was followed by a further, unblended, check by the second 
reviewer.  Extracted data was entered into an Excel (Microsoft® software) database. 
 
Data items 
The following variables were extracted: study demographics (year and country of publication, study design, 
and sample size), nature of the stricture (stricture characteristics including location, activity as active or 
quiescent fibrotic, type as de novo or anastomotic, length and diameter), preoperative radiographic 
assessment, intervention technique (dilatation time, balloon dilator size and endoscopic accessibility), 
follow-up time period and outcome measures (symptomatic response, technical response, overall 
complication and perforation rates). 
 
Risk of bias in individual studies  
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The quality of studies was assessed by using the Newcastle-Ottawa Scale.  The quality of studies was 
evaluated by examining three items: patient selection, comparability and outcome (Table 1 Supplementary 
material).    
 
 
Summary measures 
Symptomatic response was defined by the resolution of symptoms, technical response by the passage of the 
scope following endoscopic balloon dilatation and adverse events by the proportion of patients who develop 
complications. Outcomes are expressed as pooled event rates (with 95% confidence interval limits), or as a 
proportion of the size of the population studied (patients), stricture numbers (strictures) and/or number of 
dilatation procedures performed (interventions).  
 
Synthesis of results  
Continuous numerical data is expressed as means (with standard deviations) or as medians (with range 
values).  A per patient analysis was used to determine the cumulative proportion of patients within a group, 
per stricture analysis was used to determine the cumulative proportion of strictures within a group and a per 
dilatation analysis was used to determine the cumulative proportion of dilatations within a group.  All three 
analyses were expressed as proportions and percentages.  A per study analysis was used to assess pooled 
event rates across studies.  The random effects model was used and results were expressed with forest plots 
and summative statistics.   
 
Risk of bias across studies 
Heterogeneity across studies was assessed visually with forest plots and numerically (I
2
 < 25% indicates low 
heterogeneity).  Evidence of publication bias was assessed visually using funnel plots. Comprehensive 
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Meta-analysis (CMA, Biostat, Inc.) programme was used.  To assess the relationship of continuous variables 
on outcome, the pooled mean event rate for each outcome was transformed into a dichotomous form (less 
than or greater than the stated pooled mean event rate).   
 
 
Additional analyses 
To determine association between stricture characteristics and outcome subgroup analyses were performed.  
The pooled event rates and 95% confidence interval were expressed per outcome for each categorical 
variable (e.g. balloon diameter, duration of inflation, geography and pre-interventional imaging).  The mean 
value of pooled outcomes was used to create two groups, < or ≥ the pooled mean event rate, to compare the 
effect of the proportion of patients within each group (e.g. stricture activity and stricture type) on outcome.   
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RESULTS 
Study selection 
Figure 1 details the study selection flow chart.  Two hundred and three studies were identified following 
both the initial and secondary database search.  Studies were screened according to the above eligibility 
criteria and 30 studies were included as part of a full text review.  A total of 25 studies were included in the 
final review (Table 1).   
Page 11 of 62 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
Table 1 - Study demographics, frequency of population size, strictures and dilatations - Description of 
studies included in the literature review. A total number of 1089 subjects were described in the literature 
with 790 strictures undergoing 2664 interventions. Most were females (557/1023 [54%]) and most studies 
described both E and S outcomes [E = 8, S = 6 and E, S = 11]
 
Author Country 
Study 
Design 
Population 
Size 
Number Of 
Strictures 
Number Of 
Dilatations 
Number 
Of 
Females 
Study 
Outcome 
Ajlouni Y,
[20]
 2006 Australia R 37 83 113 22 E 
Atreja,
[21]
 2014 USA R 128 169 430 73 E 
Bahlme,
[22]
 2013 
United 
Kingdom 
R 79 93 191 
47 E,S 
Blomberg,
[23]
 1991 Sweden P 27 ns ns 16 S 
Breysem,
[24]
 1992 Belgium P 18 20 24 13 E,S 
Brooker,
[25]
 2003 
United 
Kingdom 
R 14 14 26 
6 S 
Couckuyt,
[26]
 1995 Belgium P 55 59 78 35 E,S 
De Angelis,
[27]
 2013 France R 26 27 46 15 E,S 
East J.E,
[29]
 2007 
United 
Kingdom 
RCT 13 ns ns 5 E 
Endo,
[30]
 2013 Japan P 30 47 83 8 E 
Ferlitsch,
[31]
 2006 Austria P 46 ns 73 26 Su 
Foster,
[32]
 2008 USA R 24 29 71 18 S 
Gustavsson,
[33]
 2012 Sweden R 125 ns 594 59 E 
Honzawa,
[34]
 2013 Japan R 25 29 83 6 E 
Hunter,
[28]
, 2001 
United 
Kingdom 
R 22 ns 71 
16 S 
Mueller,
[35]
 2010 Germany P 55 74 93 34 E,S 
Nanda,
[36]
 2013 Ireland P 31 ns 55 14 E,S 
Ramboer,
[37]
 1995 Belgium P 13 15 53 5 S 
Sabate,
[38]
 2003 France R 38 41 53 18 E,S 
Scimea,
[39]
 2011 Italy P 37 39 72 14 E,S 
Singh,
[40]
 2005 USA R 17 20 29 10 E,S 
Stienecker,
[41]
 2009 Germany P 25 31 50 20 E 
Thomas-Gibson,
[43]
 2003 
United 
Kingdom 
R 59 ns 124 
ns E,S 
Van Assche,
[42]
 2010 Belgium R 138 ns 237 77 E,S 
Williams A.J.K,
[44]
 1991 
United 
Kingdom 
R 7 ns 15 ns E 
TOTAL 1089 790 2664 557   
RCT = Randomised Control Trials; R = Retrospective; P = Prospective; ns = not specified;                                     
Study Outcome Measures: S = Symptomatic response, E = Endoscopic / Technical response, Su = Surgery 
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They included 10 prospective studies (N=10), 14 retrospective studies (N=14) and 1 randomised control trial 
(N=1).
[20-44]
  Publication dates ranged from 1991 to 2014 and originated from European,
[22-29 31 33 35-39 41-44]
 (6 
studies from the United Kingdom),
[22 25 28 29 43 44]
 North American,
[21 32 40]
 Japanese,
[30 34]
 and Australian,
[20]
 
institutions. 
 
Study Characteristics 
The cumulative data for the 25 studies 
[20-44]
 included 1089 patients, 790 strictures and 2664 dilatations.  
Fifty-one percent (557/1089) were females, 43% (466/1089) were males and for the remaining 8% 
(66/1089) gender was unspecified.  The median age at first dilatation reported across 17 studies (determined 
from the mean age at first dilatation per study) was 41.1 (range = 32.5 - 50).
[21 23-28 30 32 34 36-42]
  Symptomatic 
response was reported as the outcome measure in 16 studies,
[23 25 28 32 37]
 technical response in 8 studies,
[20 21 
29 30 33 34 41 44]
  and both symptomatic and technical response in 11 studies (Table 1).
[22 24 26 27 35 36 38-40 42 43]
   
Follow-up duration was reported in 24 studies with wide variation.
[20-24 26-35]
  The median maximum follow-
up time period was 83.5 months (range 12-172).  The median minimum follow-up time period was 4 months 
(range 0 – 84). 
 
Nine studies (N=468) did not report number of strictures per patient. All but 14 of the remaining 621 cases 
from 16 studies, had >1 stricture documented.
[20-22 24-27 30 32 34 35 37-41]
 Fifteen studies examined lower 
gastrointestinal strictures only
[23 28 29 31 33 36 42 43]
 while ten included both upper and lower GI strictures.  The 
proportion of upper GI strictures was 3.8% (though due to missing data in 9 studies this was an estimation). 
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Stricture activity 
The proportion of patients with active
[22-26 37 38]
 and quiescent
[22 24-26 30 31 37 38]
 strictures was 44.9% (155/345) 
and 47.2% (151/320) respectively.  In the majority of cases 82.2% (447/544) data relating to stricture 
activity was not reported.
[22 24 25 28 33-36 39 42]
 
 
Stricture type 
Across thirteen studies (N=565)
[22-26 28 31 36-38 41-43]
, most patients (79.1%; 447/565) had anastomotic 
strictures and only (19.6%; 111/565) had de novo strictures.
[22-26 28 31 36-38 41-43]
 
 
Intervention technique 
A maximum balloon diameter of 18mm,
[24 27 28 35-37 41-43]
 20mm,
[20-22 25 29-32 34 39 40 44]
 and 25mm
[23 26 33 38]
 was 
reported across all 25 studies.  There was variation in the maximum inflation time across 23 studies with 
maximal inflation periods of one,
[22 34 35]
 two,
[20 24 26 27 32 37-44]
, 3,
[28-30]
 4, 
[23 33 36]
 and 5 minutes 
[31]
. 
 
Imaging 
The majority of studies describe pre-interventional imaging (18/20; 90%)
[21 22 25-31 33 35 36 38-43]
 and only two 
studies did not (2/20; 10%).
[20 32]
  The median maximum length of strictures reported across 21 studies was 
7cm (range 3 - 25cm). 
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Synthesis of Results 
Symptomatic response 
Fifteen studies reported on symptomatic response for patient numbers (N = 615)
[22-28 31 32 35-37 39 40 42 43]
 which 
was 63.9% (393/615) (Table 2).  Fourteen of these were from Europe (612/653 [93.7%]) spanning 7 
different countries (four from the UK)
[22-28 35-39 42 43]
 and 2 were North American studies (41/653 [6.3%]).
[32 
40]
  The proportion of females and males was 51.8% (338/653) and 39.2% (256/653) respectively. One study 
did not report on gender proportions (n = 59).
[43]
  The median age at first dilatation reported across 13 
studies reporting on symptomatic response (determined from the mean age at first dilatation per study) was 
42.6 (range 33.7-50).
[23-28 32 36-40 42]
 
Author, Year 
Number of patients (dilatations*) reporting 
symptomatic response (n) / sample size 
Percentage of patients (or 
dilatations*) (%) 
Blomberg,
[23]
 1991 22 / 27 81 
Breysem,
[24]
 1992 8 / 18 44 
Ramboer,
[37]
 1995 11 / 13 85 
Couckuyt,
[26]
 1995 34 / 55 62 
Hunter,
[28]
, 2001 16 / 22 73 
Brooker,
[25]
 2003 11 / 14 79 
Thomas-Gibson,
[43]
 2003 24 / 59 41 
Sabate,
[38]
 2003 47 / 53 * 89 * 
Singh,
[40]
 2005 13 / 17 76 
Foster,
[32]
 2008 22 / 24 92 
Mueller,
[35]
 2010 42 / 55 76 
Van Assche,
[42]
 2010 61 / 138 44 
Scimea,
[39]
 2011 30 / 37 81 
Nanda,
[36]
 2013 14 / 31 45 
De Angelis,
[27]
 2013 24 / 26 92 
Bahlme,
[22]
 2013 61 / 79 77 
Total 
¥
 393 / 615  63.9 
* Sabate et al
[38]
 reported symptomatic response from the number of dilatations performed, not the 
number of patients receiving dilatation. 
¥ Sabate et al
[38] 
excluded from cumulative analysis. 
 
Table 2. Proportions of reported symptomatic response outcomes following endoscopic balloon 
dilatation - Fifteen studies (n=615) reported symptomatic outcome per patient and one study per dilatation 
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procedure. The number of patients reporting improvement in each study is shown. A total of 393 (63.9%) 
patients reported symptomatic response with dilatation. One study reported response rate for the number of 
dilatations 89%. 
 
Analysis of pooled study outcomes demonstrated a symptomatic response rate of 70.2% [95% CI: 60-
78.8%] with evidence of moderate to high heterogeneity between studies [I
2
: 63.8%] (Figure 2).  On 
exclusion of the six outlier publications,
[24 27 32 36 42 43]
 the symptomatic response rate was 74.8% (95% CI: 
69.6-79.3%; I
2
: 0.0%) (Figure 3).  The symptomatic response rate in one study was measured according to 
the number of dilatations done and was reported as 89% (47/53).
[38] 
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A comparison between symptomatic response rates and other variables is shown in Table 3.   
Variable Symptomatic response Technical response Perforation 
Categorical variables represented as pooled event rates % (95% Confidence Intervals) 
Balloon 
diameter 
(millimetres) 
18 61.9 (47.4 – 74.4) 94.7 ( 87-97.9) 3.1 (1.9-5.1) 
20 79.5 (72.6-85) 90.6 (87.4-93.0) 3.8 (2.2-6.5) 
25 71 (48 – 86.6) 89.4 (86.9-91.5) 2.2 (1.3-3.6) 
Duration of 
inflation 
(minutes) 
2 70.6 (58.1-80.6) 92.2 (86.6-95.5) 3.1 (1.8-5.3) 
5 67.1 (41.9 – 85.2) 92.6 (84.2-96.7) 3.6 (1.6-8.2) 
Geography 
European 67.9 (57-77.2) 90.6 (86.7-93.5) 2.3 (1.6-3.3) 
North 
American 
84.5 (62.6 – 94.7) 91.6 (86.8-94.8) 5.0 (1.3-17.7) 
Japanese  91.3 (81.9-96.0)  
Pre-
interventional 
imaging 
Reported 70.4 (58.8 – 79.8) 92.3 (85.8-95.9) 2.7 (1.8-4.0) 
 
Table 3. The relationship between response rates (symptomatic and technical) and adverse event rates (perforation) with categorical variables – The 
categorical variables (balloon diameter, duration of inflation, geography and pre-interventional imaging) are presented as pooled event rates across studies 
alongside their 95% confidence intervals. 
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The proportion of patients demonstrating a higher than average compared with lower than average 
symptomatic response rate for active strictures was 60% and 73%, for anastomotic strictures was 75% and 
85% and for de novo strictures was 25% and 15% respectively. (Table 2 of supplementary material). 
 
Technical Response 
A total of 19 studies reported on technical response as an outcome measure.  Analysis for pooled study 
results demonstrated an event rate of 90.6% (95% CI: 87.8-92.8%) with low heterogeneity between studies 
(I
2
: 11.7%) (Figure 1 – Appendix: Supplementary Figures).  Fourteen studies originated from Europe across 
seven different countries.  The median age at first dilatation reported across 12 studies was 40.1 years (range 
32-49).  The proportion of females and males were 49.8% (470/943) and 43.2% (407/943) respectively. 
 
Reported outcomes were expressed either for patients (N = 435),
[22 24 29 34 35 38 39 41 42 44]
 stricture (N = 299),
[20 
21 30]
 and intervention/dilatation (N = 926) (Supplementary table 3).
[26 27 33 36 43 45]
. The proportion of patients 
demonstrating technical response was 92.6% (403/435).  The technical response rate for strictures was 
91.3% (273/299) and for balloon dilatation interventions was 90% (833/926). The pooled event analysis 
results were similar due to low heterogeneity (Figure 1 -Appendix: supplementary figures).  
The relationship between technical response rates and variables is shown in Table 3.  The proportion of 
patients demonstrating a higher than average compared with lower than average technical response rate for 
active strictures, was 51% and 52%, for quiescent strictures, was equal at 45%, for anastomotic strictures 
75% and 83% and for de novo strictures was 25% and 17% respectively.  (Table 2 in supplementary 
material).  
 
Complications and Perforations 
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Fifteen studies reported complications according to the number of patients (N = 564)
[20-22 25 26 28 32 35-37 39 40 44]
 
and four studies reported complications based on the number of dilatations (N = 1228).
[31 33 42 43]
  The 
proportion of patients and dilatations with complications was 4.4% (25/564) and 5.2% (64/1228).  Analysis 
of pooled study data demonstrated an overall complication rate of 6.4% (95% CI: 5.0 – 8.2; I
2
: 4.0%).   
 
Eighteen studies reported on perforation for patients (N = 654)
[20-28 34-41 44]
 and four studies for number of 
dilatations (N = 1281).
[31-33 42 43]
  The proportion of patients and dilatations that were followed by perforation 
was 2.4% (16/654) and 1.8% (23/1281) respectively. Study data analysis showed no heterogeneity across 
studies with a pooled mean perforation rate of 3% (95% CI: 2.2- 4.0%; I
2
: 0%) (Supplementary figure 2).   
 
The relationship between perforation rates and variables is shown in Table 3. Balloon inflation diameters of 
18mm,
[24 27 28 34-37 41-43]
 20mm,
[20-22 25 31 34 39 40 44]
 and 25mm
[23 26 33 37]
 demonstrated pooled mean perforation 
rates of 3.1% (95% CI: 1.9-5.1%; I
2
 0%), 3.8% (95% CI: 2.2-6.5%; I
2
 0%), and 2.2% (95% CI: 1.3-3.6%; I
2
 
0%) respectively.  An inflation time of up to 2 minutes
[22 24 26-28 32 35-37 39 40 42 43]
 and 5 minutes
[23 30 33 35]
 
demonstrated a pooled mean perforation rate of 3.1% (95% CI: 1.8-5.3%; I
2
 0%) and 3.6% (95% CI: 1.6-
8.2%; I
2
 0%) respectively. The mean perforation rate across 18 European studies that reported perforation 
according to the number of patients was 2.3% (95% CI: 1.6-3.3%; I
2
 0%).
[22-28 31 33 35-39 41-44]
  The mean 
perforation rate across three North American studies was 5.0% (95% CI: 1.3-17.7%; I
2 
0%) (Table 5).
[21 32 40]
  
The use of pre-interventional imaging was described across 14 studies
[21 22 26 27 30 33 35 36 38-43]
 where the 
pooled mean perforation rate was 2.7% (95% CI: 1.8-4.0%; I
2
 0%).  The perforation rate in one study that 
did not use pre-interventional imaging was 1.3% (95% CI: 0.1-17.8%).
[20]
 The median maximum stricture 
length reported across 20 studies was 7cm (range 2-25cm).  
The proportion of patients with higher than average compared with lower than average perforation rates for 
active strictures was 62% and 36%, for quiescent strictures was 38% and 55%, for anastomotic strictures 
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was 81% and 7% and for de novo strictures was 19% and 21% respectively. (Table 2 Supplementary 
material) 
 
 
Surgery 
Surgery was required for one or more of the following two events: (i) inaccessible strictures during 
endoscopy and (ii) persistent or recurrent symptoms i.e. failed repeated dilatation. 
 
 (i) Endoscopic inaccessibility 
Seven studies reported 12.9% of cases (33/256) where endoscopic balloon dilatation could not be completed 
during endoscopy either because the stricture was too narrow or there was acute angulation.
[24 26 31 35 38 39 44]
  
Two studies (N = 130) reported this event 6.9% (9/130) by number of strictures.
[20 30]
  
 
 (ii) Symptomatic disease 
Twenty one studies reported surgical outcomes for ongoing recurrent disease despite repeated balloon 
dilatation according to the number of patients (N = 849).
[20-28 31-41 44]
  The proportion of patients who 
underwent surgery was 21.1% (179/849).  Pooled data demonstrated a mean surgical event rate of 23.3% 
(95% CI: 20-26.5), with low heterogeneity demonstrated across studies (I
2
: 13.2%) (Supplementary figure 
3). One study reported the requirement of surgery according to the number of strictures (N = 47).
[30]
  The 
proportion of strictures requiring surgery in this study was 29.8% (14/47). 
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DISCUSSION 
This is the most comprehensive systematic review of endoscopic balloon dilatation for the management of 
Crohn’s strictures to date.  
 
Summary of evidence 
This review offers insights into endoscopic balloon dilatation for Crohn’s strictures on which to build future, 
more robust, study designs to measure efficacy. The pooled event rate for symptomatic response of 74.8% 
excludes 6 studies identified as outliers from the funnel plot. However, the distribution of the studies within 
the plot also suggests publication bias may be over-estimating the effect size. Incomplete data on the number 
of cases where access failed during an endoscopic procedure may contribute to the over-estimation of the 
effect size. In this review it was only reported in 24% of the studied population with a failure rate of 13%. 
Failure of endoscopic access is particularly relevant as the majority of strictures undergoing dilatation are 
likely to be anastomotic and associated with adhesions and fibrosis.  In contrast, a previous systematic 
review on endoscopic balloon dilation indicated a 58 % response comparable to our 63.9% expressed as the 
proportion of patients but a lower value than the pooled effect.
[19]
  Since the pooled summative effect 
addresses weight and heterogeneity between studies, it reflects a more accurate measure of efficacy albeit 
subject to bias.  
The review reveals other relevant observations pertaining to the intervention. Where the studies examined 
both symptomatic and technical response, the former was consistently less than the technical rate of 90.6%. 
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The inferences is that passage of the endoscope through the stricture is an inadequate outcome for patients.  
There was a wide variation in dilatation techniques suggesting an overriding need for standardisation of 
endoscopic procedures. A balloon diameter of 20mm seems to be commonest, and the most effective size 
limit, consistent with the internal small bowel diameter of 25mm. Two minutes of dilatation is the 
commonest duration used and may be associated with better outcomes. The most effective dilatation 
technique is a three step increase in diameter with regular repeat procedures until resolution of symptoms on 
a normal diet.   
The study focused on an adult population with a mean age at first dilatation of 41 years, which reflects their 
aetiology as a complication of the disease or surgery. Additional analyses to assess factors that might 
influence outcomes were undertaken by using the mean value of pooled outcomes to create two groups, < or 
≥ the pooled mean event rate, in order to compare the effect of different variables on outcomes. There were 
more patients with stricture inflammation, in the below average than above average symptomatic response 
group; in parallel more non-inflamed strictures were associated with above average symptomatic response. 
For anastomotic strictures, more patients were in the below average than above average symptomatic and 
technical response groups. This observation is counter-intuitive as anastomotic strictures tend to be shorter 
but perhaps it shows that there is greater resistance of fibrotic strictures to dilatation. With respect to 
dilatation technique maximum balloon diameter and duration of inflation did not seem to show different 
outcomes, except that 20mm size was accompanied by higher symptomatic response rate than 18mm (80% 
vs 52%).  There was no evidence of higher perforation rate with dilatation diameters of 25mm. North 
America symptomatic response rates were higher than Europe but were associated with higher complication 
rates. More inflammatory were in the above average perforation group and more quiescent strictures were in 
the below average perforation group.   
Overall pooled complication rate was 6.4% [95% CI: 5.0 – 8.2], much higher than complication rates of 2% 
reported by Hassan.
[19]  
In contrast, the perforation rate, which represents the most significant complication, 
was 3% [95% CI: 2.2- 4.0%] for pooled analysis and similar to that expressed as proportion of patient in this 
study (2.6%). The previous review by Hassan did not report perforation and a separate event.
[19]
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Whilst the strength of this review lies in the systematic manner in which it was conducted in accordance 
with PRISMA guidelines and methods for narrative reviews, it is beset by several limitations 
(46)
. 
 
Limitations  
Firstly, the absence of control groups meant that we were unable to compare the impact of variables on 
outcome measures and the meta-analysis focused on summative effect in relation to heterogeneity. We used 
an average effect to gauge whether an event occurred above or below mean rate so the relationships shown 
in these analyses should be interpreted with caution.  
The second limitation was the diversity of the populations studied in terms of stricture characteristics, 
techniques and expression of results according to sample size, stricture numbers or number of interventions. 
This made comparisons across the studies difficult particularly for outcomes which expressed results 
according to sample size, stricture numbers and/or number of interventions. We used population size for 
primary outcomes of this review. Thirdly incomplete and variable reporting of some population and 
interventional characteristics mean analyses were conducted on data that were available and may not be 
generalizable to other studies or populations. This limitation explains why the number of strictures was less 
than the sample number of the review (790 and 1089). Fourthly, most studies were reported by 
gastroenterologists, with a bias towards showing endoscopic benefit through both performance and reporting 
bias. Lastly, none of the studies mention dietary restrictions on follow-up:  low fibre diet will be associated 
with better and sustained response than a resumption to a full diet at the expense of quality of life.   
 
Conclusions 
This review measures the efficacy of endoscopic balloon dilation for treatment of Crohn’s strictures: 74.8% 
response rate may be an overestimate due to publication bias and yet a more accurate estimate of the 
previous reports of 58% which did not use a pooled event rate. Whilst there is a suggestions that some 
strictures may respond better than others this is far from conclusive due to the lack of a control group but 
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merely indicates that further studies should take into account the extent and severity of inflammation in 
strictures. It draws attention to variation in intervention techniques between studies, inadequacy of outcome 
measure and deficiency in pre-assessment for suitability of dilatation.  
There is a discernible absence of randomised controlled trial of endoscopic balloon dilatation for Crohn’s 
strictures. This reflects the difficulty of a comparable control and the ethical dilemma of using sham 
intervention or surgery.  Surgery is usually reserved for longer strictures and less so for non-accessible 
strictures because double balloon enteroscopy increased access to small bowel strictures. Anti-TNF 
therapies have a role in the treatment of strictures through anti-inflammatory effects that increase the 
diameter of the bowel lumen and also reduce TNF-induced fibrosis.
[47 48]
  Drug therapy as a control arm may 
be a more acceptable option to address the question of the optimal small bowel preserving treatment for 
Crohn’s strictures. The challenge of a control arm is not the only barrier to conclusive results. The other is 
an optimal and comparable outcome measure that capture relief of obstructive symptoms, resumption of 
normal dietary intake, quality of life and monitoring for repeat stenosis or fibrosis. Further exploratory 
studies on this aspect are warranted.  
Endoscopic balloon dilatation plays an important role in the management of Crohn’s strictures. The risk 
benefit profile depends on several stricture factors. Some strictures may be more effectively managed with 
surgery. Others may be treated with anti-TNF therapy to reduce fibrosis and inflammation with or without 
balloon dilatation to break down the collagen fibres. Future studies exploring this should also examine how 
imaging and biochemical markers, may guide treatment decisions. Reproducible outcome measures with 
scores to represent inflammatory vs fibrotic components as end-points will allow for comparison across 
studies. There is already some research in this field which is demonstrating promising results 
[49]
. Without 
these studies an evidence-based management pathway that reduce variation and set standards in care for 
Crohn’s strictures cannot be developed. 
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Section/topic  # Checklist item  Reported on page #  
TITLE  1 
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT  2 
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Supplementary file 
structure summary 
INTRODUCTION  5 
Rationale  3 Describe the rationale for the review in the context of what is already known.  5 - 6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
6 
METHODS  7 
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
7, 
Figure 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Figure 1 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data 
synthesis.  
8; Table 1 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9 
Page 34 of 62Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
35 
 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
9 
 
Page 1 of 2  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
9 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
10 
RESULTS  11 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
11; Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
13;  
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Supp. Table 1 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 2, Figure 2-3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
Page 15 – 21, Figure 
3, supp. Figures 1-3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Page 15 – 21, Figure 
2 – 5. 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
Page 19 – 24; 
Tables 3,  
Sup. table 3 
DISCUSSION  25 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
22 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
23 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 24 
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future research.  
FUNDING  32 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
32 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Figure 1 – Flow chart demonstrating the search strategy in accordance with PRISMA  – Two hundred and 
three (n=203) records were identified following duplicate removal. Fifty three (n=53) records were removed 
after limits were applied. One hundred and fifty (n=150) records underwent screening and one hundred and 
twenty records were excluded (n=120). Thirty records (n=30) were assessed for eligibility and twenty five 
(n=25) articles were included in our quantitative analysis.  
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Figure 2 – Funnel plot for studies reporting on symptomatic response rate - Heterogeneity across studies 
was demonstrated (I2: 63.8%). Six studies[24 27 32 36 42 43] were outliers and determined as sources for 
publication bias on sensitivity analysis.  
211x97mm (96 x 96 DPI)  
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Figure 3 – Forest plot for studies reporting on symptomatic response following exclusion of outlier studies[24 
27 32 36 42 43] – Random effects model demonstrating a pooled event rate for symptomatic response as 
74.8% (95% CI: 69.6 – 79.3%; I2: 0%).  
191x142mm (96 x 96 DPI)  
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Supplementary Tables 
Author, year Selection Comparability Outcome Score 
Ajlouni Y,
[20]
 2006 *** - ** *** 
Atreja,
[21]
 2014 *** - ** ** 
Bahlme,
[22]
 2013 *** - ** **** 
Blomberg,
[23]
 1991 ** - * **** 
Breysem,
[24]
 1992 * - * ***** 
Brooker,
[25]
 2003 **** - ** ****** 
Couckuyt,
[26]
 1995 *** - * ***** 
De Angelis,
[27]
 2013 *** - ** **** 
East J.E,
[29]
 2007 ** - * **** 
Endo,
[30]
 2013 *** - ** **** 
Ferlitsch,
[31]
 2006 *** - * ***** 
Foster,
[32]
 2008 *** - * **** 
Gustavsson,
[33]
 2012 *** - ** **** 
Honzawa,
[34]
 2013 *** - ** ***** 
Hunter,
[28]
, 2001 *** - ** ***** 
Mueller,
[35]
 2010 *** - ** ***** 
Nanda,
[36]
 2013 *** - ** ***** 
Ramboer,
[37]
 1995 ** - ** ***** 
Sabate,
[38]
 2003 *** - * ***** 
Scimea,
[39]
 2011 *** - ** ***** 
Singh,
[40]
 2005 *** - * ***** 
Stienecker,
[41]
 2009 ** - ** ***** 
Thomas-Gibson,
[43]
 2003 *** - ** *** 
Van Assche,
[42]
 2010 *** - ** **** 
Williams A.J.K,
[44]
 1991 *** - * ***** 
 
Table 1 – Quality assessment of studies using the Newcastle-Otawa scale – The maximum 
number of stars each study can receive is 9 (maximum 4 for selection, 2 for comparison and 3 
for outcome.  The median number of stars across studes was 5 (range: 2 – 6). 
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Table 2. The relationship of response (symptomatic and technical) and adverse outcomes expressed in dichotomous form (< or ≥ the 
pooled mean event rate) with continuous variables (stricture activity and stricture type).  (a) For symptomatic response in relation to (i) 
stricture activity, 73 patients were in the lower PMER and 171 patients were in the higher PMER groups.  Comparison of the lower PMER with 
higher PMER group, showed more active strictures (73% vs 60%) and less quiescent strictures (25% vs 33%) (ii) stricture type, 323 patients 
were in the lower PMER and 171 patients were in the higher PMER groups. Comparing the lower with higher PMER groups, there were more 
anastomotic strictures (85% vs 75%) and less de novo strictures (15% vs 25%).  (b) For technical response in relation to (i) stricture activity, 56 
patients were in the lower than average PMER group and 164 patients were in the higher than average PMER group.  There were no differences 
in stricture activity between high and low technical response groups (ii) stricture type, 115 patients were in lower than average PMER group 
and 328 patients in higher than average PMER.  Comparing the lower PMER group with higher PMER group, there were more anastomotic 
strictures (83% vs 75%) and less de novo strictures (17% vs 25%). (c) For perforation, in relation to (i) stricture activity, 170 patients were in 
 
Symptomatic response 
a 
Technical  response  
b 
Perforation 
c 
Pooled Mean Event Rate 
PMER 
74.8% (95% CI: 69.6-79.3%) 90.6% (95% CI: 87.8-92.8%) 3% (95% CI: 2.2- 4.0%) 
Dichotomous Outcome < PMER ≥ PMER < PMER ≥ PMER < PMER ≥ PMER 
 
Continuous variables % ( N / Population size ) 
Stricture 
activity 
Active 73 (53/73) 60 (102/171) 52 (29/56) 51 (84/164) 36 (62/170) 62 (93/150) 
Quiescent 25 (18/73) 33 (57/171) 45 (25/56) 45 (73/164) 55 (94/170) 38 (57/150) 
Stricture 
type 
Anastomotic 85 (274/323) 75 (128/171) 83 (95/115) 75 (246/328) 77 (217/282) 81 (230/283) 
De novo 15 (49/323) 25 (43/171) 17 (20/115) 25 (82/328) 21 (58/282) 19 (53/283) 
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the lower than average perforation rate group and 150 patients were in the higher than average group.  Comparing the higher perforation with 
lower perforation groups, there were more active strictures (62% vs 36%) and less quiescent strictures (38% vs 55%) (ii) stricture type, there a 
282 patients in the lower than average perforation group and 283 patients in the higher than average perforation group.  Comparison of the 
higher perforation with lower perforation groups, there were similar numbers of anastomotic strictures (81% vs 77%) and de novo strictures 
(19% vs 21%).  PMER: pooled mean event rate. 
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Author, Year 
Number of 
patients (n)  
Technical 
response rate 
(%) 
Bahlme 
22
, 2013 75 95 
Breysem 
24
, 1992 16 89 
East J.E 
29
, 2007 12 92 
Honzawa 
34
, 2013 22 88 
Mueller 
35
, 2010 52 95 
Sabate 
38
, 2003 32 84 
Scimea 
39
, 2011 31 84 
Stienecker 
41
, 2009 24 96 
VanAssche 
42
, 2010 134 97 
Williams A.J.K 
44
, 1991 5 71 
Total 403 93 
Author, Year 
Number of 
strictures (n)  
Technical 
response rate 
(%) 
Ajlouni Y
 20
, 2006 75 90 
Atreja 
21
, 2014 154 91 
Endo 
30
, 2013 44 94 
Total 273 91 
Author, Year 
Number of 
balloon 
dilatations 
(n) 
Technical 
response rate 
(%) 
Couckuyt 
26
, 1995 70 90 
De Angelis 
27
, 2013 46 100 
Gustavsson 
33
, 2012 533 90 
Nanda 
36
, 2013 55 100 
Singh 
40
, 2005 28 97 
Thomas-Gibson 
43
, 
2003 
101 81 
Total 833 61 
 
Table 3 - Proportions of reported technical response outcomes following endoscopic 
balloon dilatation - Ten studies (n=435) reported a technical response outcome per patient, 
three per stricture (n=299) and six per balloon dilatation procedure (n = 1356). The number 
of patients, stricture and balloon dilatations reporting improvement in each study is shown. A 
total of 403 (92.6%) patients, 273 (91.3%) strictures and 833 (61.4%) balloon dilatations 
reported technical response with dilatation.
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Supplementary Material - Figures 
 
Figure 1– Forest plot for studies reporting on technical response – A random effects model demonstrating a pooled technical response event 
rate of 90.6% (95% CI: 87.8 – 92.8%; I2: 11.7%) with reported outcomes expressed for  number of patients (3, 5, 10, 15, 16, 19, 20, 22, 23, 25), strictures (1, 
2, 11)
 and interventions/dilatations (7, 8, 14, 17, 24, 26). 
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Supplementary Figure 2 – Forrest plot reporting on perforation rates – A random effects model demonstrating a pooled perforation rate of 
3% (95% CI: 2.2-4.0%; I2: 0%) across 22 studies with reported outcomes expressed according to number of patients,[20-28 34-41 44] balloon 
dilatation,[31-33 42 43] and strictures.[30]    
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Supplementary Figure 3 – Forrest plot reporting on the rate of surgical intervention in the event of a failed clinical outcome – A random 
effects model demonstrating a pooled surgical intervention rate of 23.3% (95% CI: 20-26.5; I2: 13.2%) across reported outcomes expressed 
according to the number of patients.[20-28 31-41 44] 
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Supplementary material – supplementary text 
RESULTS 
Description of population for symptomatic response outcomes 
Stricture activity 
There was variation in the reporting of stricture activity.  Eight studies reported stricture 
activity expressed for number of patients (N = 290) 
(23-27, 32, 38, 39)
.  The proportion of patients 
with active and quiescent strictures was 53.4% (155/290) and 41.7% (121/290) respectively.  
One study reported disease activity based on number of strictures (N = 20) 
(41)
.  The 
proportion of strictures that showed active and no inflammation was 80% (16/20) and 20% 
(4/20) respectively. 
Stricture type 
Twelve studies described stricture types for patient numbers (N = 540) 
(23-27, 29, 32, 37-39, 43, 44)
.  
The proportion of patients with anastomotic and de novo strictures was 80.5% (435/540) and 
18.1% (98/540).  Five studies expressed stricture types as a proportion of total stricture 
numbers (N = 189) 
(28, 33, 36, 40, 41)
.  The proportion of active and de novo strictures was 45.5% 
(86/189) and 54% (102/189).  
Intervention technique 
Balloons inflated up to 18mm 
(25, 28, 29, 36-38, 43, 44)
, 20mm 
(23, 26, 33, 40, 41)
, and 25mm 
(24, 27)
 
demonstrated a pooled mean symptomatic response rate of 61.9% (95% CI: 47.4 – 74.4%; I
2
 
27%), 79.5% (95% CI: 72.6-85%; I
2
 0%) and 71% (95% CI: 48 – 86.6%; I
2
 0%) respectively. 
The mean symptomatic response rate with a balloon dilatation duration of up to 2 minutes 
(23, 
25, 27, 28, 33, 36, 38, 40, 41, 43, 44)
 and up to 5 minutes 
(24, 29, 37)
 was 70.6% (95% CI: 58.1-80.6%; I
2
 
9.1%) and 67.1% (95% CI: 41.9 – 85.2%; I
2
 0%) respectively. 
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Geography  
Comparison of European and North American symptomatic success rate, which may reflect 
different patient characteristics or techniques, showed the pooled mean symptomatic success 
rate of 67.9% (95% CI: 57-77.2%; I
2
 2%) in Europe studies 
(23-29, 36-38, 40, 43, 44)
 compared with 
84.5% (95% CI: 62.6 – 94.7%; I
2
 0%) in North American studies 
(33, 41)
. 
Imaging 
The pooled mean symptomatic response rate across twelve studies that described the use of 
pre-interventional imaging was 70.4% (95% CI: 58.8 – 79.8%; I
2
 0%) 
(23, 26-29, 36, 37, 39-41, 43, 44)
.  
The median maximum stricture length across fifteen studies was 7cm (range 3 - 25cm). 
 
Description of population for technical response outcomes 
Stricture activity 
Seven studies reported on the stricture activity.  Five studies assessed activity based on the 
number of patients (N = 220) 
(23, 25, 27, 31, 39)
.  The proportion of patients with active and 
quiescent strictures was 51.4% (113/220) and 44.5% (98/220) respectively.  Only two studies 
reported on disease activity according to the stricture population (N = 189) 
(22, 41)
.  The 
proportion of strictures that demonstrated active and quiescent disease was 59.2 % (112/189) 
and 35.4% (67/189) respectively. 
Stricture type 
Seventeen studies reported on whether the stricture was anastomotic or de novo.  Eight 
studies assessed this as per the number of patients (N = 443) 
(23, 25, 27, 37, 39, 42-44)
. The 
proportion of patients with anastomotic and de novo strictures were 77% (341/443) and 23% 
(102/443).  Eight studies assessed stricture type as per the number of strictures involved 
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(N=488) 
(21, 22, 28, 31, 35, 36, 40, 41)
. The proportion of anastomotic and de novo strictures was 
42.8% (209/488) and 57.2% (279/488) respectively. Only one study assess stricture type as 
per the number of balloon dilatation performed (N = 594) 
(34)
. The proportion of anastomotic 
and de novo strictures in this study was 81.6% (487/597) and 17.9% (107/597) respectively. 
Intervention technique 
Balloons inflated up to 18mm 
(25, 28, 36, 37, 42-44)
, 20mm 
(21-23, 30, 31, 35, 40, 41, 45)
, and 25mm 
(27, 34, 39)
 
reported a pooled mean technical success rate of 94.7% (95% CI: 87-97.9%; I
2
 0%), 90.6% 
(95% CI: 87.4-93.0%; I
2 
39.3%), and 89.4% (95% CI: 86.9-91.5%; I
2
 0%) respectively.  An 
inflation time of up to 2 minutes 
(23, 25, 27, 28, 36, 40, 41, 43, 44)
 and up to 5 minutes 
(31, 34, 37)
 
demonstrated a pooled mean technical success rate was 92.2% (95% CI: 86.6-95.5%; I
2
 0%) 
and 92.6% (95% CI: 84.2-96.7%; I
2
 20.6%) respectively. 
Geography 
The pooled mean technical success rates across the 14 European 
(23, 25, 27, 28, 30, 34, 36, 37, 39, 40, 42-
45)
, 2 North American 
(22, 41)
  and 2 Japanese 
(31, 35)
 studies were 90.6% (95% CI: 86.7-93.5%; 
I
2
 18.8%), 91.2% (95% CI: 87.8-93.8%; I
2
 0%) and 91.3% (95% CI: 81.9-96.0%; I
2
 0%), 
respectively.  
Imaging 
The pooled mean technical success rate across 15 studies that reported the use of pre-
dilatation imaging to further define the stricture was 91.4% (95% CI: 88.3-93.8%; I
2
 13.8%) 
(23, 30, 36, 39, 40, 43)
. The median maximum stricture length reported across 17 studies is 7.2cm 
(range 3cm – 25cm)   
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Description of population for perforation outcomes 
Stricture Activity 
There were nine studies that reported stricture activity according to the number of patients (N 
= 320) 
(23-27, 29, 31, 32, 38, 39)
.  The proportion of patients with active and quiescent disease was 
48.4% (155/320) and 47.1% (151/320) respectively.  There are two studies that reported 
disease activity according to the number of strictures (N = 189) 
(22, 41)
.  The proportion of 
active and quiescent strictures in these studies were 59.2% (112/189) and 35.4% (67/189). 
Stricture type  
There were 12 studies that reported the type of stricture according to the number of patients 
(N = 540) 
(23-27, 29, 32, 37-39, 43, 44)
.  The proportion of patients with anastomotic and de novo 
strictures was 80.5% (435/540) and 20.5% (111/540). Nine studies reported the type of 
stricture according to the number of strictures (N = 517) 
(21, 22, 28, 31, 33, 35, 36, 40, 41)
. The 
proportion of anastomotic and de novo strictures was 42.7% (221/517) and 57% (295/517). 
Technique 
Balloon inflation diameters of 18mm 
(25, 28, 29, 35-38, 42-44)
, 20mm 
(21-23, 26, 32, 35, 40, 41, 45)
 and 
25mm 
(24, 27, 34, 38)
 demonstrated pooled mean perforation rates of 3.1% (95% CI: 1.9-5.1%; I
2
 
0%), 3.8% (95% CI: 2.2-6.5%; I
2
 0%), and 2.2% (95% CI: 1.3-3.6%; I
2
 0%) respectively.  An 
inflation time of up to 2 minutes 
(23, 25, 27-29, 33, 36-38, 40, 41, 43, 44)
 and 5 minutes 
(24, 31, 34, 36)
 
demonstrated a pooled mean perforation rate of 3.1% (95% CI: 1.8-5.3%; I
2
 0%) and 3.6% 
(95% CI: 1.6-8.2%; I
2
 0%) respectively.  
Geography 
The mean perforation rate across 18 European studies that reported perforation according to 
the number of patients was 2.3% (95% CI: 1.6-3.3%; I
2
 0%) 
(23-29, 32, 34, 36-40, 42-45)
.  The mean 
Page 55 of 62 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
perforation rate across three North American studies was 5.0% (95% CI: 1.3-17.7%; I
2 
0%) 
(22, 33, 41)
. 
Imaging 
The use of pre-interventional imaging was described across 14 studies 
(22, 23, 27, 28, 31, 34, 36, 37, 39-
44)
 where the pooled mean perforation rate was 2.7% (95% CI: 1.8-4.0%; I
2
 0%).  The 
perforation rate in one study that did not use pre-interventional imaging was 1.3% (95% CI: 
0.1-17.8%) 
(21)
.  The median maximum stricture length reported across 20 studies was 7cm 
(range 2-25cm). 
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2. STRUCTURED SUMMARY 
Background 
Endoscopic balloon dilatation is a recognised treatment for symptomatic Crohn’s strictures. 
Several case studies report its short term and long term efficacy.  A systematic analysis of the 
current literature is needed to define its overall efficacy and inform the design of future 
studies.  
Objectives 
The aims of the review were to examine symptomatic response, technical response and 
adverse events of endoscopic balloon dilatation. Stricture characteristics that may impact on 
outcome were also explored. 
Data sources 
A systematic search strategy of COCHRANE, MEDLINE, EMBASE and OVID was 
performed in accordance with PRISMA guidelines.   
Study Eligibility Criteria 
Original studies (including randomised controlled trials, observational reports and case series 
with sample size more than 5) reporting outcomes of endoscopic balloon dilatation for 
Crohn’s disease intestinal strictures. 
Participants and Interventions 
Patients with Crohn’s intestinal strictures undergoing endoscopic balloon dilatation in the 
adult population (age > 16). 
Study Appraisal and Synthesis Methods 
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The quality of individual studies was assessed by using the Newcastle-Ottawa Scale.  A per 
patient analysis was used to determine the cumulative proportion of patients within a group.  
A per study analysis was used to assess pooled event rates across studies.  The random effects 
model was used and results were expressed with forest plots and summative statistics. 
Heterogeneity across studies was assessed visually with forest plots and numerically.   
Results 
Twenty-five studies were included in the final review capturing 1089 patients, 790 strictures 
and 2664 dilatations.  Overall, the proportion of patients who achieved symptomatic and 
technical response was 63.9% (393/615) and 92.6% (403/435) respectively. The proportion of 
patients who experienced perforation was 2.6% (18/700).  The pooled event rates for 
symptomatic and technical response was 74.8% (95% CI: 69.9-79.3%) and 90.6% (95% CI: 
87.8 – 92.8%) with no (I
2
: 0.0%) and moderate heterogeneity (I
2
: 11.7%) respectively. The 
pooled event rates for complications was 6.4% (95% CI: 5.0 – 8.2; I
2
: 4.0%) and perforation 
was 3% (95% CI: 2.2-4.0%; I
2
: 0%) respectively. Inflammatory activity may be associated 
with lower symptomatic response and higher perforation rate. More anastomotic strictures, 
were associated with low symptomatic and technical response rates.  
Limitations 
The lack of control groups precluded comparisons between the effects of variables on 
outcome measures directly. Selection bias is anticipated to influence the magnitude of 
response. Most studies were reported by gastroenterologists, with a bias towards showing 
endoscopic benefit as both performance and reporting biases. 
Conclusions and implications of key findings 
Endoscopic balloon dilatation for symptomatic Crohn’s strictures shows high efficacy with a 
low complication rate. Efficacy may be affected by active inflammation, previous surgery 
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and choice of outcome measure. Future studies should identify valid, precise and relevant 
outcome measures and examine differential effects on stricture types. 
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FIGURE LEGENDS 
 
Figure 1 – Flow chart demonstrating the search strategy in accordance with PRISMA  – Two hundred 
and three (n=203) records were identified following duplicate removal. Fifty three (n=53) records were 
removed after limits were applied. One hundred and fifty (n=150) records underwent screening and one 
hundred and twenty records were excluded (n=120). Thirty records (n=30) were assessed for eligibility and 
twenty five (n=25) articles were included in our quantitative analysis. 
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Figure 2 – Funnel plot for studies reporting on symptomatic response rate - Heterogeneity across 
studies was demonstrated (I
2
: 63.8%). Six studies
[24 27 32 36 42 43]
 were outliers and determined as sources for 
publication bias on sensitivity analysis. 
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Figure 3 – Forrest plot for studies reporting on symptomatic response following exclusion of outlier 
studies
[24 27 32 36 42 43]
 – Random effects model demonstrating a pooled event rate for symptomatic response 
as 74.8% (95% CI: 69.6 – 79.3%; I
2
: 0%). 
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